Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type1 diabetes

Diabetic Medicine

Volumn 28, Issue 9, 2011, Pages 1028-1033

  Mcdonald, T J ^a,b   Colclough, K ^c   Brown, R ^b   Shields, B ^a   Shepherd, M ^a   Bingley, P ^d   Williams, A ^d   Hattersley, A T ^a   Ellard, Sian ^a,c  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b Department of Clinical Chemistry and Immunology ^*  (United Kingdom)

^c ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Autoantibodies; GAD antibodies; GAD65; IA 2 antibodies; Maturity onset diabetes of the young

Indexed keywords

GLUTAMATE DECARBOXYLASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; PANCREAS ISLET CELL ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MATURITY ONSET DIABETES MELLITUS; MATURITY ONSET DIABETES OF THE YOUNG; PREVALENCE;

ADULT; AUTOANTIBODIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE;

EID: 80051653635     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03287.x     Document Type: Article

References (30)

1. Ellard S, Bellanne-Chantelot C, Hattersley AT. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008; 51: 546-553.
2. Lambert AP, Ellard S, Allen LI, Gallen IW, Gillespie KM, Bingley PJ et al. Identifying hepatic nuclear factor 1α mutations in children and young adults with a clinical diagnosis of type1 diabetes. Diabetes Care 2003; 26: 333-337.
3. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362: 1275-12781.
4. Barker JM. Clinical review. Type1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 2006; 91: 1210-1217.
5. Lendrum R, Walker G, Gamble DR. Islet-cell antibodies in juvenile diabetes mellitus of recent onset. Lancet 1975; 1: 880-882.
6. Maclaren NK, Huang SW, Fogh J. Antibody to cultured human insulinoma cells in insulin-dependent diabetes. Lancet 1975; 1: 997-1000.
7. MacCuish AC, Irvine WJ, Barnes EW, Duncan LJ. Antibodies to pancreatic islet cells in insulin-dependent diabetics with coexistent autoimmune disease. Lancet 1974; 2: 1529-1531.
8. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151-156.
9. Bonifacio E, Lampasona V, Bingley PJ. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol 1998; 161: 2648-2654.
10. Hawkes CJ, Wasmeier C, Christie MR, Hutton JC. Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Diabetes 1996; 45: 1187-1192.
11. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337-1339.
12. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type1 diabetes. Proc Natl Acad Sci U S A 2007; 104: 17040-17045.
13. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997; 46: 1701-1710.
14. Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type1 diabetes. Diabetes Care 2000; 23: 1326-1332.
15. Nyunt O, Wu JY, McGown IN, Harris M, Huynh T, Leong GM et al. Investigating maturity onset diabetes of the young. Clin Biochem Rev 2009; 30: 67-74.
16. Xu JY, Dan QH, Chan V, Wat NM, Tam S, Tiu SC et al. Genetic and clinical characteristics of maturity-onset diabetes of the young in Chinese patients. Eur J Hum Genet 2005; 13: 422-427.
17. Aguilera E, Casamitjana R, Ercilla G, Oriola J, Nicoletti F, Gomis R et al. Clinical characteristics, B-cell function, HLA classII and mutations in MODY genes in non-paediatric subjects with Type1 diabetes without pancreatic autoantibodies. Diabet Med 2005; 22: 137-143.
18. Bowden SA, Hoffman RP. Triple diabetes: coexistence of type1 diabetes mellitus and a novel mutation in the gene responsible for MODY3 in an overweight adolescent. Pediatr Diabetes 2008; 9: 162-164.
19. Miura J, Sanaka M, Ikeda Y, Watanabe C, Nakagami T, Iwasaki N et al. A case of type-1 diabetes mellitus formerly diagnosed as maturity-onset diabetes of the young (MODY) carrying suggestive MODY3 gene. Diabetes Res Clin Pract 1997; 38: 139-141.
20. Gach A, Wyka K, Pietrzak I, Wegner O, Malecki MT, Mlynarski W. Neonatal diabetes in a child positive for islet cell antibodies at onset and Kir6.2 activating mutation. Diabetes Res Clin Pract 2009; 86: e25-27.
21. Schober E, Rami B, Grabert M, Thon A, Kapellen T, Reinehr T et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type2 diabetes mellitus in children and adolescents: experience from a large multicentre database. Diabet Med 2009; 26: 466-473.
22. Eide SA, Raeder H, Johansson S, Midthjell K, Sovik O, Njolstad PR et al. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study). Diabet Med 2008; 25: 775-781.
23. Hartemann-Heurtier A, Simon A, Bellanne-Chantelot C, Reynaud R, Cave H, Polak M et al. Mutations in the ABCC8 gene can cause autoantibody-negative insulin-dependent diabetes. Diabetes Metab 2009; 35: 233-235.
24. Molven A, Ringdal M, Nordbo AM, Raeder H, Stoy J, Lipkind GM et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type1 diabetes. Diabetes 2008; 57: 1131-1135.
25. Rubio-Cabezas O, Edghill EL, Argente J, Hattersley AT. Testing for monogenic diabetes among children and adolescents with antibody-negative clinically defined Type1 diabetes. Diabet Med 2009; 26: 1070-1074.
26. Nilson E, Ekholm B, Rees Smith B, Torn C, Hillman M. Calcium addition to EDTA plasma eliminates falsely positive results in the RSR GADAb ELISA. Clin Chim Acta 2008; 388: 130-134.
27. Brooking H, Ananieva-Jordanova R, Arnold C, Amoroso M, Powell M, Betterle C et al. A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta 2003; 331: 55-59.
28. Rahmati K, Lernmark A, Becker C, Foltyn-Zadura A, Larsson K, Ivarsson SA et al. A comparison of serum and EDTA plasma in the measurement of glutamic acid decarboxylase autoantibodies (GADA) and autoantibodies to islet antigen-2 (IA-2A) using the RSR radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits. Clin Lab 2008; 54: 227-235.
29. Torn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51: 846-852.
30. Borg H, Marcus C, Sjoblad S, Fernlund P, Sundkvist G. Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes. Acta Paediatr 2000; 89: 46-51.